Aardvark Therapeutics Reports Q2 2025 Net Loss of $14.4 Million Amid Increased R&D Expenses

Aardvark Therapeutics Inc reported a Q2 2025 net loss of $14.4 million, up from $5.4 million in Q2 2024, driven by higher R&D expenses of $13.1 million. The company maintains a strong cash position of $141.8 million and is advancing its clinical programs, including the expansion of the Phase 3 HERO trial for ARD-101 and the initiation of Phase 2 trials for ARD-201. Aardvark's financial stability supports ongoing and future clinical trials and operations projected into 2027.

Aardvark Therapeutics Inc. (AARD) reported its financial results for the second quarter ended June 30, 2025, with a net loss of $14.4 million, up from $5.4 million in the same period last year. The increase in net loss was primarily due to higher research and development (R&D) expenses, which totaled $13.1 million for the quarter [1].

The company maintains a strong cash position, with $141.8 million in cash, cash equivalents, and short-term investments as of June 30, 2025. This financial stability supports Aardvark's ongoing and future clinical trials and operations, projected into 2027 [1].

Aardvark is advancing its clinical programs, with several notable developments. The Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) is being expanded to include pediatric patients under the age of 13. This expansion aims to reach a larger segment of the PWS patient population and serve more patients in need [1].

Additionally, Aardvark is initiating two Phase 2 trials for ARD-201, an investigational oral obesity therapy. The POWER trial will focus on preventing weight regain in patients discontinuing glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, while the STRENGTH trial will evaluate durable weight loss as a monotherapy and in combination with GLP-1RA [1].

The company also bolstered its leadership team in May 2025 with strategic hires across scientific, commercial, regulatory, and legal functions. These appointments include Timothy Kieffer, Ph.D., as Chief Scientific Officer; Danny Villeneuve as Chief Commercial Officer; Terrie Kellmeyer, Ph.D., as Senior Vice President, Regulatory Affairs; and Christian Zapf, J.D., as General Counsel [1].

References:
[1] https://www.biospace.com/press-releases/aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and-business-updates